317 related articles for article (PubMed ID: 30037229)
1. Peptide-Based
De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
[TBL] [Abstract][Full Text] [Related]
2. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
[TBL] [Abstract][Full Text] [Related]
3. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
[TBL] [Abstract][Full Text] [Related]
4. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
5. Development of [
Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
[TBL] [Abstract][Full Text] [Related]
6. Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S
Biochem Biophys Res Commun; 2017 Jan; 483(1):258-263. PubMed ID: 28025143
[TBL] [Abstract][Full Text] [Related]
7. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H
Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880
[TBL] [Abstract][Full Text] [Related]
8. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
9. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model.
Jiang J; Li D; Liu T; Xia L; Guo X; Meng X; Liu F; Wang F; Yang Z; Zhu H
Bioorg Med Chem Lett; 2021 May; 40():127901. PubMed ID: 33705912
[TBL] [Abstract][Full Text] [Related]
11. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
[TBL] [Abstract][Full Text] [Related]
12. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
13. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1.
Jouini N; Cardinale J; Mindt TL
ChemMedChem; 2022 Jun; 17(12):e202200091. PubMed ID: 35388635
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
16. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
18. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
[TBL] [Abstract][Full Text] [Related]
19. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]